Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

Patient Comment on Mobocertinib for Exon 20

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation

In Brief for June 22, 2022

Journal of Thoracic Oncology Impact Factor Surpasses 20

Step It Up For Research!

Foundation Announces 2022 Young Investigator Grant Recipients

Workshops Offer Opportunities for Education, Networking Based on Shared Interests, Specialties

WCLC Chairs Welcome Opportunity to Gather Face-to-Face